Table 1.
Demographic, treatment, and clinical variables
| Pre-Covid | Lockdown | Pre-Vaccination | Vaccination | |
|---|---|---|---|---|
| Age, years, mean (SD) | 41.91 (12.19) | 45.66 (12.27) | 44.92 (12.39) | 45.37 (12.63) |
| Sex, female (%) | 65% | 66% | 66% | 65% |
| Individual Treatment Period (N) | ||||
| Interferon beta 1 | 2,646 | 1,004 | 1,139 | 1,135 |
| Glatiramer acetate | 773 | 301 | 366 | 356 |
| Fingolimod | 1,219 | 346 | 741 | 804 |
| Alemtuzumab | 75 | 0 | 1 | 0 |
| Cladribine | 9 | 1 | 11 | 20 |
| Ocrelizumab | 209 | 11 | 63 | 418 |
| Dimethyl fumarate | 1,206 | 682 | 848 | 989 |
| Natalizumab | 580 | 362 | 445 | 565 |
| Months of treatment duration, mean (SD) | 42.22 (17.92) | 2.03 (0.43) | 5.53 (1.11) | 9.81 (2.14) |
| MPR, mean (SD) | 0.98 (0.20) | 1.11 (0.27) | 0.99 (0.22) | 0.94 (0.26) |
| MPR > 80%, number (%) | 84% | 93% | 85% | 82% |
| Charlson comorbidity index | ||||
| 0 | 2,597 | 27 | 458 | 1,033 |
| 1–2 | 60 | 0 | 5 | 23 |
| > = 3 | 2 | 0 | 0 | 0 |